Global Disease Burden of Hepatitis B Tops SPT Week in Review

5. Consolidation: Reshaping Pharmacy and Beyond

There is a concern that mergers and acquisitions in the pharmacy space will lead to decreased competition and loose agreements between companies that will not drive significant outcomes. Read more.

4. FDA Approves Second Biosimilar to Neupogen

The FDA approved Pfizer's filgrastim-aafi, a filgrastim biosimilar to Amgen's Neupogen. Read more.

3. Injection Drug Users Can Benefit from a Partially Effective Hepatitis C Vaccine

Researchers estimated whether a hepatitis C vaccine could reduce transmission of the virus among injection drug users, even without providing complete immunity. Read more.

2. FDA OKs New Drug for Endometriosis Pain Management

Officials with the FDA have approved elagolix (Orilissa, AbbVie), a product specifically developed for women with moderate to severe endometriosis pain. Read more.

1. Global Treatment Coverage of Hepatitis B Lagging

Taking advantage of cost-effective generic medications can improve access to hepatitis B treatment, especially in countries with a high disease burden. Read more.